Who are Folotyn and Leucovorin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Liposomal doxorubicin hydrochloride, S-1 [Tegafur/Oteracil/gimeracil], TS-1 and cisplatin, cetuximab + cisplatin + vinorelbine, cytarabine and mitoxantrone, S-1 plus Cisplatin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/folotyn-and-leucovorin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Folotyn and Leucovorin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Folotyn and Leucovorin (Folotyn and Leucovorin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antineoplastic agent. Area: Oncology.

phase 2 Antineoplastic agent Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Folotyn and Leucovorin (Folotyn and Leucovorin) — Acrotech Biopharma Inc.. Folotyn is a pegylated form of calicheamicin, a potent antitumor antibiotic that binds to DNA and inhibits RNA synthesis, while Leucovorin is a folate analog that inhibits dihydrofolate reductase, thereby increasing the effectiveness of folate-dependent drugs.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Folotyn and Leucovorin TARGET	Folotyn and Leucovorin	Acrotech Biopharma Inc.	phase 2	Antineoplastic agent
Liposomal doxorubicin hydrochloride	Liposomal doxorubicin hydrochloride	Cephalon, Inc.	marketed	Antineoplastic agent	DNA and topoisomerase II
S-1 [Tegafur/Oteracil/gimeracil]	S-1 [Tegafur/Oteracil/gimeracil]	AstraZeneca	phase 3	Antineoplastic agent	Thymidylate synthase
TS-1 and cisplatin	TS-1 and cisplatin	Taiho Pharmaceutical Co., Ltd.	phase 3	Antineoplastic agent	DNA
cetuximab + cisplatin + vinorelbine	cetuximab + cisplatin + vinorelbine	Merck KGaA, Darmstadt, Germany	phase 3	Antineoplastic agents	EGFR
cytarabine and mitoxantrone	cytarabine and mitoxantrone	Pfizer	phase 3	Antineoplastic agents
S-1 plus Cisplatin	S-1 plus Cisplatin	Taiho Pharmaceutical Co., Ltd.	phase 3	Antineoplastic agents	Thymidylate synthase, DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antineoplastic agent class)

Acrotech Biopharma Inc. · 1 drug in this class
Asan Medical Center · 1 drug in this class
AstraZeneca · 1 drug in this class
Beijing Biostar Pharmaceuticals Co., Ltd. · 1 drug in this class
Cephalon, Inc. · 1 drug in this class
Jiangsu Hansoh Pharmaceutical Co., Ltd. · 1 drug in this class
Seattle Project Corporation · 1 drug in this class
Taiho Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Folotyn and Leucovorin — Competitive Intelligence Brief. https://druglandscape.com/ci/folotyn-and-leucovorin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab